Valyu
Science & R&D

Peer-reviewed science, one API call away.

Full-text papers, clinical trials, patents and structured databases for the AI your research teams rely on. Every answer comes back with its sources.

Get an API keyExplore Life Sciences ↗Talk to us →
valyu · search
QUERYWhat is the human genetic and clinical evidence for PCSK9 as a target for lowering cardiovascular risk?
  • Planning the search
  • Searching PubMed, PMC full text, ClinicalTrials.gov
  • Reading full text and results tables
  • Writing a cited answer

Loss-of-function variants in PCSK9 lower LDL cholesterol and are associated with a substantially lower risk of coronary heart disease 1. Gain-of-function mutations cause familial hypercholesterolaemia, which fixes the direction of effect 2.

Evolocumab reduced major cardiovascular events on top of statins in the FOURIER outcomes trial 3.

[1]Cohen JC et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEJM, 2006.Journal
[2]Abifadel M et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 2003.Journal
[3]Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. NEJM, 2017.Trial
Illustrative output
Teams building AI on real science
SanofiFrancis Crick InstituteMITStorkeOxfordBotnar InstituteBerkeleyCambridgeHarvardAxil CapitalUCLPacific NW National LabPolymerizeYonsei UniversityHolistic AIJožef Stefan InstituteSichuan Huiyu PharmaceuticalGachon UniversityHunt Regional HealthcareKerala Ayurveda
72.7%

on DRACO, the long-form research benchmark, across deep research, medicine and scholarly research.

ScholarQA-Multi
89%

Biology, chemistry and medicine literature synthesis

MedAgent
48%

Hard medical questions, ahead of Google, Exa and Parallel

Sources
100+

Web, academic, biomedical, legal and financial

Fields

Choose your field.

Same API, same sources. Each page is written for the people in that field.

Field
Biotech & Pharma

Evidence for every stage, from target to label.

5 pipeline stages
Field
Medtech & Diagnostics

Clinical and regulatory evidence for design, submission and surveillance.

Evidence · CER · surveillance
Field
Chemistry & Materials

Reported properties pulled from tables, with their conditions attached.

Extraction · patents
Field
Physics & Engineering

arXiv, patents and CERN open data for hardware and physical R&D.

arXiv · patents · CERN
For researchers
Academia & Research

Full-text search in your terminal, for reviews, papers and lab agents.

Free to start
Not sure where you fit?
See every source.

Seven data layers and 100+ sources, filterable by field.

Coverage

Why full text

Science needs sources, not generic search.

Full text, not abstracts.

Methods, results and supplementary tables, not the 250-word summary.

A source for every claim.

Answers return with citations to the papers, trials and patents they came from.

Licensed for commercial use.

Proprietary journals, cleared for use inside your products and internal tools.

Built for agents.

REST, MCP and SDKs, so your agent searches the record like any other tool.

Full text

Drag to see what an abstract leaves out.

Most AI tools read the abstract. The methods, results tables and supplements are where the evidence is.

NEJM · 2006
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH
Abstract
Methods
Results · Table 2
GenotypenLDL-CCHD risk
Supplementary appendix
NEJM · 2006
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH
Abstract
Methods
Not in the abstract
Results · Table 2
Not in the abstract
Supplementary appendix
Not in the abstract
Abstract onlyValyu, full text

Products

Two ways to use the scientific record.

Search when your agent needs the evidence. DeepResearch when you need the whole review. Both return sources.

Search API

Cited full text for your agent, in one call.

Ask in plain language and get passages, tables and figures back from papers, trials, labels and patents, each linked to its source. For agents that reason over the evidence themselves.

How Search works →
DeepResearch

A literature review, run for you.

Give it a research question. It plans the searches, reads the full text, checks the claims and returns a cited report. Heavy mode scores 72.7% on DRACO.

How DeepResearch works →
Connect it your way
One promptDevelopers with a coding agentSet up Valyu by following https://www.valyu.ai/agents.mdGuide →
MCP connectorScientists in Claude, ChatGPT or Cursormcp.valyu.ai/mcpSet up →
API and SDKsPlatform and ML teamspip install valyuDocs →
Valyu BioAnyone trying it firstbio.valyu.aiOpen ↗

Also works with LangChain·LlamaIndex·Vercel AI SDK·Anthropic·OpenAI·Google·AWS Bedrock·n8n·CLI·Claude Code plugin

Benchmarks

State of the art across the science that matters.

ScholarQA-Multi

Accuracy on scientific-literature synthesis across biology, chemistry and medicine.

Valyu89%
Prometheus81%
OpenScholar78%
PaperQA272%
All benchmarks →Methodology on GitHub →

Use cases

The work it does.

Discovery & R&D

Find, rank and test ideas against everything already published.

Target discovery →Lead optimisation →Materials discovery →Lab agents →

Clinical & regulatory

Trials, clearances, labels and precedents, read alongside the literature.

Clinical development →Regulatory & access →Device clinical evidence →

Evidence synthesis

Screen, extract and summarise a literature, with the audit trail kept.

Systematic reviews →Clinical evaluation reports →Property extraction →

Diligence & scouting

Check the science, trial record and IP behind an asset or technology.

Biotech diligence →Patent landscapes →

Writing & review

Drafts and checks where every claim carries its source.

Medical affairs →Grant & paper writing →
Storke cut clinical evaluation timelines in half — grounding every assessment in the primary literature instead of hand-searching it.
— Storke
PubMed
Wiley
ClinicalTrials.gov
DailyMed
openFDA
bioRxiv
medRxiv
ChemRxiv
arXiv
ChEMBL
PubChem
Open Targets
NCBI Gene
ClinVar
dbSNP
USPTO
EPO
PubMed
Wiley
ClinicalTrials.gov
DailyMed
openFDA
bioRxiv
medRxiv
ChemRxiv
arXiv
ChEMBL
PubChem
Open Targets
NCBI Gene
ClinVar
dbSNP
USPTO
EPO

FAQ

Questions researchers ask.

Is the content licensed for commercial use?
Yes. Valyu’s licensed sources are cleared for use inside commercial products and internal tools.
How fresh is the data?
Clinical trials and drug labels update in real time, patents weekly, and PubMed and the preprint servers monthly.
Can I restrict answers to peer-reviewed sources?
Yes. Choose sources per request, from peer-reviewed journals only to journals plus preprints, trials and patents.
Does it work with my agent framework?
Yes. Use the REST API or the MCP server. Valyu works with Claude Code, Codex, Gemini CLI and the Vercel AI SDK.
Which plan includes the science sources?
Free sign-up credits cover every source. After that, PubMed and arXiv are on every plan, clinical trials and drug labels from Comfortably Pro, and ChEMBL, PubChem, Open Targets, genomics and patents on Serious Business.
ENTERPRISE

Enterprise on Valyu.

Private indexes on your firm's internal data, enterprise controls, and engineers who ship with you.

Talk to our team
Security and reliability
Security and reliability

SOC 2, Zero Data Retention, SSO with SAML or OIDC, scoped tenant isolation. US, EU, and UK deployment options, or dedicated in your VPC.

Private Index
Private Index

State-of-the-art retrieval on internal data: lab notebooks, internal reports, trial data, research archives. Agents run on your own research and every Valyu source, in one call.

Forward Deployed Engineers
Forward Deployed Engineers

When the API needs to go further, our engineers ship with you. Custom DeepResearch agents and vertical indexes tuned to your field.

Everything your scientists read, behind one API call.

Try this queryHuman genetic evidence linking TYK2 to autoimmune disease
Get startedTalk to us
  • 37M+PubMed papers
  • 500K+clinical trials
  • 150K+drug labels
  • 100M+compounds
  • 12M+patents